Axla stock : Axcella Therapeutics (NASDAQ:AXLA) Axcella Therapeutics (NASDAQ:AXLA), an innovative biotechnology company in the clinical stage that is pioneering an innovative approach to treat complicated diseases by using multi-targeted, EMF (EMM) compositions today announced its earnings for the quarter as well as the full year that ended on the 31st of December, 2021. Axcella also gave a business update.
2021 was a year of notable accomplishments in the history of Axcella Therapeutics that was highlighted by the launch of three Phase 2 studies in the field of non-alcoholic steatohepatitis (NASH) as well as overt hepatic cerebrovascular encephalopathy (OHE) and our most recent area of study Long COVID. We were thrilled to keep our momentum going in the early 2022 time frame by receiving the Fast Track approval to AXA1125 for NASH and liver fibrosis stated Bill Hinshaw, President and Chief Executive Director of Axcella. A data-rich time is close to being completed and we have the release of both Long COVID Phase 2a top-line results as well as the NASH phase 2b interim results to be announced for the quarter ending in March. With these developments and a recently strengthened balance sheet, and the possibility of other value drivers that are on the time frame, we believe the right conditions have been created for a transformative 2022.
Axcella Health Returns vs. S&P
| 1 YEAR | 5 YEAR | 5 YEAR ANNUALIZED | SINCE IPO | |
|---|---|---|---|---|
| AXLA | -76.52% | -97% | ||
| S&P | -14.16% | +39.80% | +6.93% | +37% |
Assets
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Net Cash | $25.43M | -2.6% |
| Accounts Receivable | – | – |
| Inventory | 0 | – |
Liabilities
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Long Term Debt | $16.11M | -35.6% |
| Short Term Debt | $11.48M | – |
Ratios
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Return On Assets | -152.8% | +133.1% |
| Return On Invested Capital | -77.2% | +24.1% |
Cash Flow
QUARTERLYANNUAL
| Q3 2022 | YOY CHANGE | |
|---|---|---|
| Free Cash Flow | -$19.15M | +37.5% |
| Operating Free Cash Flow | -$18.94M | +35.9% |
Valuation
QUARTERLYANNUAL
| Q4 2021 | Q1 2022 | Q2 2022 | Q3 2022 | YOY CHANGE | |
|---|---|---|---|---|---|
| Price to Earnings | – | – | – | – | – |
| Price to Book | 2.25 | 2.77 | 3.57 | 9.68 | +312.7% |
| Price to Sales | – | – | – | – | – |
| Price to Tangible Book Value | 2.25 | 2.77 | 3.57 | 9.68 | +312.7% |
| Price to Free Cash Flow TTM | – | – | – | – | – |
| Enterprise Value to EBITDA | -4.73 | -3.92 | -4.41 | -5.44 | +10.8% |
| Free Cash Flow Yield | – | – | – | – | – |
| Return on Equity | -132.7% | -149.6% | -257.4% | -543.2% | +445.3% |
| Total Debt | $25.07M | $28.35M | $28.06M | $27.59M | +10.3% |
